Skip to main content

New Zealand in the global regulatory landscape

Medsafe's international participation

Medsafe participates in the International Medical Device Regulators Forum (IMDRF), the body that coordinates international regulatory harmonisation for medical devices. IMDRF guidance is a key reference for Medsafe in areas not explicitly covered by the Medicines Act 1981.

New Zealand's regulatory framework is most closely aligned with the GHTF (Global Harmonization Task Force) model — the predecessor to IMDRF — and through that, with the original EU Medical Devices Directive framework.


Regulatory comparison

FeatureNZ (Medsafe)AU (TGA)EU (MDR)US (FDA)UK (MHRA)CA (Health Canada)
Pre-market approvalNoYesYesYesYesYes
Market entry mechanismWAND notificationARTG listingCE marking510(k)/PMA/De NovoUKCA/MHRA registrationMedical Device Licence
Formal conformity assessmentNoYesYes (Notified Bodies)YesYes (Approved Bodies)Yes
UDI requirementNoYes (staged)YesYesYesYes
PSUR requiredNoFor someYesNo (equivalent)YesFor some
IVD separate frameworkNoYesYes (IVDR)YesYesYes
Primary legislationMedicines Act 1981Therapeutic Goods Act 1989EU MDR 2017/745FD&C ActUK MDR 2002Medical Devices Regulations

Multi-market submission strategy

For manufacturers targeting NZ as part of a broader APAC or global strategy:

NZ + AU — the most common pairing. The TTMRA provides a natural bridge. Use a single Sponsor for both markets where possible. Australian TGA evidence directly satisfies NZ conformity requirements.

NZ + EU + AU — CE certification and TGA listing together cover most global market entry evidence needs. NZ WAND notification is then administratively straightforward.

NZ standalone — possible but rare. Manufacturers entering NZ without other major market approvals need to be prepared to hold strong technical documentation, as there is no Notified Body or TGA process to generate conformity evidence.


Exporting from New Zealand

Devices manufactured in New Zealand and exported to other markets must meet the regulatory requirements of those destination markets — not just NZ's Medicines Act. A NZ manufacturer exporting to the EU must comply with EU MDR; exporting to Australia requires TGA registration; exporting to the US requires FDA clearance or approval.

For export-only devices not supplied in NZ, Cabinet has confirmed that the Medical Products Bill will not require NZ regulatory approval — consistent with Australia's approach for export-only goods.